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Abstract
Objective
To assess dose-response eﬀects of the anti-CD20monoclonal antibody ofatumumab on eﬃcacy
and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis
(RMS).
Methods
Patients (n = 232) were randomized to ofatumumab 3, 30, or 60 mg every 12 weeks,
ofatumumab 60 mg every 4 weeks, or placebo for a 24-week treatment period, with a primary
endpoint of cumulative number of new gadolinium-enhancing lesions (per brain MRI) at week
12. Relapses and safety/tolerability were assessed, and CD19+ peripheral blood B-lymphocyte
counts measured. Safety monitoring continued weeks 24 to 48 with subsequent individualized
follow-up evaluating B-cell repletion.
Results
The cumulative number of new lesions was reduced by 65% for all ofatumumab dose groups vs
placebo (p < 0.001). Post hoc analysis (excluding weeks 1–4) estimated a ≥90% lesion
reduction vs placebo (week 12) for all cumulative ofatumumab doses ≥30 mg/12 wk. Dose-
dependent CD19 B-cell depletion was observed. Notably, complete depletion was not nec-
essary for a robust treatment eﬀect. The most common adverse event was injection-related
reactions (52% ofatumumab, 15% placebo), mild to moderate severity in 97%, most commonly
associated with the ﬁrst dose and diminishing on subsequent dosing.
Conclusion
Imaging showed that all subcutaneous ofatumumab doses demonstrated eﬃcacy (most robust:
cumulative doses ≥30 mg/12 wk), with a safety proﬁle consistent with existing ofatumumab
data. This treatment eﬀect also occurred with dosage regimens that only partially depleted
circulating B cells.
Classification of evidence
This study provides Class I evidence that for patients with RMS, ofatumumab decreases the
number of new MRI gadolinium-enhancing lesions 12 weeks after treatment initiation.
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therapeutic and diagnostic
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Selectively targeting B cells with anti-CD20 monoclonal
antibodies (mAbs), initially shown with genetically engi-
neered chimeric rituximab1,2 and subsequently with the hu-
manized ocrelizumab,3,4 has proved highly eﬀective at limiting
disease activity in patients with relapsing forms of multiple
sclerosis (RMS). These studies used intravenous dosing that
essentially depletes circulating B cells and substantially
reduces the development of new brain lesion activity based on
MRI.3,4 However, whether eﬃcacy could be obtained with
incomplete peripheral B-cell depletion is of considerable in-
terest, especially considering longer-term treatment in
patients with chronic disease. The current study used a range
of subcutaneous dose regimens of the human anti-CD20mAb
ofatumumab to identify the minimally eﬀective dose for the
treatment of RMS.
Ofatumumab binds to a small-loop epitope of CD20 close to
the cell surface, inducing eﬃcient complement-dependent
cytotoxicity and antibody-dependent cell-mediated cyto-
toxicity, even when CD20 expression is low.5,6 Intravenous
ofatumumab is approved for the treatment of chronic lym-
phocytic leukemia. A small phase 2 dose-escalation study
indicated that intravenous ofatumumab at B-cell–depleting
doses (100, 300, and 700 mg) resulted in a robust (≈99%)
reduction in new MRI lesion activity in patients with RMS.7
Development of subcutaneous ofatumumab anti-CD20
therapy could simplify administration and has been dem-
onstrated to be well tolerated when used in a small rheu-
matoid arthritis (RA) study.8
The aim of this study (Ofatumumab Subcutaneous Admin-
istration in Subjects With Relapsing-Remitting Multiple
Sclerosis [MIRROR]) was to determine whether a range of
doses of subcutaneous ofatumumab reduced new brain lesion
development in patients withRMS andwhether dose-dependent
B-cell depletion and repletion kinetics could be demonstrated
with anti-CD20 antibody therapy.
Methods
Patients
Eligibility criteria are detailed in the e-supplement, links.lww.
com/WNL/A437. Brieﬂy, the trial enrolled patients 18 to 55
years of age with active RMS and an Expanded Disability
Status Scale (EDSS) score of 0 to 5.5. Key exclusions were
prior use of experimental agents, mAbs (except natalizumab),
or immunosuppressive agents. Prior use of other disease-
modifying therapies (DMTs) was allowed.
Standard protocol approvals, registrations,
and patient consents
The study protocol (clinicaltrials.gov NCT01457924; gsk-
clinicalstudyregister.com OMS112831) was approved by all
central and local ethics committees. All patients provided
written informed consent.
Study design, randomization, and blinding
This was a phase 2b, multicenter, randomized, double-blind,
placebo-controlled study with 4 phases: screening, 24-week
treatment, 24-week follow-up (FU), and individualized FU
(IFU) (ﬁgure 1). During the ﬁrst 12 weeks of the treatment
phase, eligible patients were randomized (2:1:1:1:2) to pla-
cebo or ofatumumab 3-, 30-, or 60-mg doses every 12 weeks or
60 mg every 4 weeks, respectively (dose selection was based
on results of an RA single subcutaneous dose study).8 The 12-
week placebo-controlled period was considered suﬃcient to
estimate eﬃcacy and dose response of ofatumumab relative to
placebo while balancing ethics concerns over prolonged pla-
cebo exposure. At week 12, all patients in the placebo group
received a single 3-mg ofatumumab dose. The treatment
schedule of all groups originally randomized to receive
ofatumumab was maintained weeks 12 to 24.
To evaluate whether tolerability to the higher ofatumumab
doses could be enhanced by administration of an initial, smaller
dose of ofatumumab (which may provide more gradual lysis of
B cells and reduce cytokine release reactions), 1 week before
their ﬁrst treatment dose (week 0), patients in the ofatumumab
30 and 60 mg groups were randomized (1:1 ratio) to receive
either placebo or a conditioning dose of ofatumumab (3 mg).
Acetaminophen and an antihistamine (cetirizine or equiva-
lent) were administered orally up to 2 hours before each
injection. Randomization was computer generated. Patients
were administered either placebo or the designated dose of
ofatumumab (1.0-mL volume each) by trained site personnel
at weeks 0, 1, 4, 8, 12, 16, and 20 to help maintain blinding of
patients, neurologists, and study staﬀ. After completion of the
treatment phase, the 24-week FU phase monitored patient
safety and B-cell repletion. From week 48, individual patients
whose CD19+ B-lymphocyte counts remained below the
lower limit of normal (LLN) and who did not start a DMT
entered the IFU phase to assess B-cell repletion.
Glossary
AE = adverse event; CI = conﬁdence interval; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale;
FU = follow-up; GdE = gadolinium-enhancing;HAHA = human anti-human antibody; IFU = individualized follow-up; IRR =
injection-related reaction; LLN = lower limit of normal;mAb =monoclonal antibodies;MFIS =Modiﬁed Fatigue Impact Scale;
MIRROR = Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis; mITT =
modiﬁed intent-to-treat; MSFC = Multiple Sclerosis Functional Composite; RA = rheumatoid arthritis; RMS = relapsing
multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SAE = serious adverse event.
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Study endpoints
Study endpoints are detailed in the e-supplement, links.lww.
com/WNL/A437. The primary eﬃcacy endpoint was deﬁned as
the cumulative number of new gadolinium-enhancing (GdE)
brain lesions at week 12 (based on T1-weighted MRI scans at
weeks 4, 8, and 12). Other MRI endpoints were the cumulative
number of new GdE lesions at week 24 and cumulative number
and total volume of new and new plus persisting GdE lesions,
new and/or newly enlarging T2 lesions, and T1-hypointense
lesions at weeks 12 and 24. Double-dose gadolinium (0.2mmol/
kg) contrast was used to enhance detection of MS lesions.9 MRI
scans were analyzed by a central vendor blinded to patient
treatment (Perceptive Informatics, Billerica, MA). Clinical eﬃ-
cacy was assessed as the proportion of patients who were relapse
free from weeks 0 to 12. Other clinical endpoints included the
EDSS, Multiple Sclerosis Functional Composite (MSFC), and
Modiﬁed Fatigue Impact Scale (MFIS) scores.
B-cell depletion and repletion kinetics were assessed by CD19+
peripheral blood B-lymphocyte counts with routine
ﬂuorescence-activated cell sorter analysis (lower limit of quan-
tiﬁcation 5 cells/μL). Ofatumumab trough concentrations were
assessed with standard enzyme-linked immunosorbent assay
(lower limit of quantiﬁcation 100 ng/mL) in all patients at weeks
12 and 24 and in a selected pharmacokinetic subpopulation at 1,
2, 3, 4, 7, 14, and 21 days after dose (n = 28).
Safety was assessed on the basis of adverse event (AE) report-
ing, the Columbia Suicidality Severity Rating Scale, vital signs,
physical and neurologic examinations, laboratory analyses, and
immunogenicity (development of human anti-human antibody
[HAHA]) with the Meso Scale electrochemiluminescence.
Statistical analysis
The primary research question was whether subcutaneous
ofatumumab reduces the development of new GdE brain
lesions in patients with RMS (Class I evidence). A sample size
of 196 patients was estimated from the Sorman et al.10 pla-
cebo estimates (and scaled for the number ofMRIs planned in
this study) to provide 90% power to detect a 63% reduction
between the highest ofatumumab dose group (60 mg every 4
weeks) and placebo and to detect a signiﬁcant dose response
at the 5% signiﬁcance level for the primary endpoint based on
a generalized linear model with underlying negative binomial
distribution (e-supplement, links.lww.com/WNL/A437).
The primary eﬃcacy population was the modiﬁed intent-to-treat
(mITT) population (all patients randomized to treatment who
took ≥1 dose of placebo or ofatumumab and who had ≥1 post-
screening MRI assessment). The primary dataset for MRI end-
points was all evaluable scans, including all on-treatment MRI
scans for each patient in themITT population, allowing estimates
of lesion rates to be calculated across the entire 12-week treat-
ment phase. AllMRI endpoint analyses were cumulative counts
(intermediate time points were not analyzed separately) and
based on preplanned screening MRI stratiﬁcation for either
no GdE lesions or ≥1 GdE lesions. To account for protocol
violations, a per-protocol population was also considered in
Figure 1 Study design
Screeningwas performed up to 6weeks before randomization. After completion (or premature discontinuation) of the 24-week treatment phase, patients entered
the 24-week follow-up, which assessed patient safety and B-cell repletion. Thereafter (week 48 onwards), individual patients whose CD19+ B-lymphocyte counts
remained below the LLNandwhodid not start aDMT, entered the IFUperiod. CD= conditioningdose; PBO= placebo; q4w= every 4weeks; q12w= every 12weeks.
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the eﬃcacy analyses (e-supplement, links.lww.com/WNL/
A437). For clinical eﬃcacy assessing relapses, the proportion
of patients relapsing in each ofatumumab dose group was
compared with placebo by the Fisher exact test.
B-cell depletion and repletion were summarized as actual counts
and change from baseline counts of CD19+ B lymphocytes.
Additional post hoc analyses were conducted with a generalized
linear model with negative binomial regression of new lesions
used as a linear function of weighted mean CD19+ B cells.
Safety analyses (descriptive statistics) were conducted on the
safety population, comprising all patients randomized and
receiving study medication. MSFC and MFIS scores were
analyzed with an analysis of covariance model adjusting for
baseline score and stratum. Safety endpoints were monitored
to the end of IFU. Time to B-cell repletion from the last
ofatumumab dose to the LLN or baseline (if less than the
LLN) was estimated with Kaplan-Meier methods.
Data availability
The results summary for this study (NCT01457924/
OMS112831) is available on clinicaltrials.gov, the default reg-
ister for GlaxoSmithKlineHuman Subject Research. If the study
does not meet the criteria for posting to clinicaltrials.gov, the
study will be available on the GlaxoSmithKline Clinical Study
Register at gsk-clinicalstudyregister.com. For interventional
studies that evaluate our medicines, anonymized patient-level
data will be made available to independent researchers, subject
to review by an independent panel, at clinicalstudydatarequest.
com within 6 months of publication. To protect the privacy of
patients and individuals involved in our studies, GlaxoSmithK-
line does not publicly disclose patient-level data.
Results
Patient disposition
In total, 232 patients were randomized, with 231 receiving ≥1
doses of study drug (analyzed as the safety population) (ﬁgure
e-1). Of these, 219 (95%) patients completed treatment
through week 12, with 214 completing through week 12 to 24.
Three of the 231 patients did not have a postbaseline MRI,
leaving 228 analyzed for eﬃcacy as the mITT population. At
week 24, 221 (96%) patients entered the FU phase, in-
cluding 7 of 17 patients who withdrew from treatment. A
total of 212 (92%) patients completed to week 48. Of the
112 patients entering the IFU phase, 88 completed this
phase (e-supplement, links.lww.com/WNL/A437). Base-
line characteristics of the safety and mITT populations were
generally balanced across treatment groups (table 1).
Efficacy
MRI endpoints
The primary outcome analysis (mITT population) demon-
strated a statistically signiﬁcant 65% reduction in the mean
rate of cumulative new GdE lesions for all ofatumumab
groups vs placebo between weeks 0 and 12 (rate ratio 0.35,
95% conﬁdence interval [CI] 0.221–0.548, p < 0.001)
(ﬁgure 2A and table 2). This eﬀect was evident as early as
week 4, when the same results are depicted as the mean
number of new GdE lesions counted at the same time points
(ﬁgure 2B). In post hoc analysis, which more closely reﬂects
the approach used in prior studies2,3 (e-supplement, links.
lww.com/WNL/A437), the reduction in the mean rate of
cumulative new GdE lesions from weeks 4 to 12 ranged from
71% (0.29 [95% CI 0.133–0.643]) to 92% (0.08 [95% CI
0.044–0.162]) across ofatumumab groups vs placebo (p ≤
0.002), with ≥90% suppression of new lesions at all cumu-
lative doses ≥30 mg over 12 weeks (0.08 [95% CI
0.044–0.162] to 0.10 [95% CI 0.056–0.187]) (table 2 and
ﬁgure e-2, links.lww.com/WNL/A435). All secondary MRI
endpoints, including the cumulative number of T2 lesions
(ﬁgure e-3, links.lww.com/WNL/A435), as well as all anal-
yses in the per-protocol population, supported the primary
analysis (tables e-1 and e-2, links.lww.com/WNL/A436).
Clinical endpoints
Overall, 26 patients relapsed during the ﬁrst 12 weeks; 11
(42%) relapsed during the ﬁrst 4 weeks (table e-3, links.lww.
com/WNL/A436). Although more relapses occurred in the
placebo group, the proportion of patients relapsing during the
ﬁrst 4 weeks (6%–13% across the ofatumumab groups vs 13%
placebo) did not diﬀer statistically (p ≥ 0.488). Over the 24-
week period, 17 (25%) patients relapsed in the placebo group
vs 3 to 10 patients (9%–22%) across the ofatumumab groups.
The proportion of relapses remained low throughout the 24-
week FU phase across all dose groups (6%–15%). There were
no signiﬁcant diﬀerences between ofatumumab and placebo
in MSFC and MFIS scores. Most patients (79%) had un-
changed EDSS scores at weeks 12 and 24 with no notable
diﬀerences between groups.
Pharmacodynamics
A dose-dependent depletion of B cells was observed, with
greater depletion for the 60-mg dose every 4 weeks (to <2% of
baseline levels at maximum depletion) and the 30- and 60-mg
dose every 12 weeks (to ≈5% of baseline) than for the 3-mg
dose every 12 weeks (to ≈25% of baseline) (ﬁgure 2C). While
all dose groups appeared to exhibit similar rates of B-cell
repopulation, time to onset of repopulation appeared longer
for the higher-dose groups. By study end, B-cell repletion was
achieved by 64% to 74% of patients across ofatumumab
groups (table e-4, links.lww.com/WNL/A436). Post hoc
analyses indicated a statistically signiﬁcant relationship be-
tween weighted mean B-cell count and new GdE lesions
(slope 0.63, 95% CI 0.41–0.85, p < 0.001) (ﬁgure e-4, links.
lww.com/WNL/A435).
Safety
In total, 43 (64%) patients receiving placebo and 121 (74%)
receiving ofatumumab (65%–81% across dose groups) experi-
enced AEs during weeks 0 to 12. During weeks 12 to 24 and 24
to 48, the proportions of patients who experienced AEs across
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treatment groups were 45% to 62% and 47% to 55%, re-
spectively (table 3). AEs were largely mild to moderate in se-
verity, and no patients died. Incidences of serious AEs (SAEs)
were 3%, <1%, 4%, and <1% in weeks 0 to 12, 12 to 24, and 24
to 48 and the IFUphase, respectively. The only SAEs to occur in
≥1 patient during the treatment phase were injection-related
reactions (IRRs), occurring in 3 patients; all continued in
the study, including 1 patient who reportedly experienced a
cytokine-release syndromewithin hours of the ﬁrst ofatumumab
(60 mg) dose. Other SAEs occurring in single patients were
cholelithiasis and hypokalemia (both with 60 mg ofatumumab
every 4 weeks) and angioedema and urticaria (both in the same
patient receiving 3 mg ofatumumab). There was no pattern of
SAEs in the 24-week FU phase. During the IFU, 2 (2%)
patients, both in the ofatumumab 60 mg every 4 weeks group,
reported a total of 2 SAEs: head injury andmalignantmelanoma
stage IV. The latter was considered treatment related, and the
patient recovered (as noted by the investigator).
The incidence of AEs was highest in the ofatumumab 60 mg
every 4 weeks group during weeks 0 to 12 of treatment (81%)
and was lowest in this group during weeks 12 to 24 (45%).
The most common week 0 to 12 AEs in the ofatumumab
groups were IRRs (41%–66% vs 15% for placebo, table e-5,
links.lww.com/WNL/A436, and ﬁgure e-5, links.lww.com/
WNL/A435). Their incidence was similar for each regimen
regardless of preconditioning dose (table e-6, links.lww.com/
WNL/A436). Most IRRs were of mild to moderate severity,
resolved the same or following day, and were associated pri-
marily with the ﬁrst ofatumumab dose (29%–50%); their
incidence diminished with subsequent ofatumumab dosing
(1%–18% at week 12).
Overall rates of any infection-related AEs were similar across
treatment groups (table e-5, links.lww.com/WNL/A436),
with no cases of opportunistic infections (including pro-
gressive multifocal leukoencephalopathy) or hepatitis B
reactivation. There were no clinically meaningful changes in
mood, vital signs, or laboratory parameters, including cyto-
penias. Four patients (3 at 3 mg and 1 at 30 mg ofatumumab)
had a single positive result for HAHAs during the treatment
phase (all titers ≤32), and 1 patient (3 mg) also had a positive
titer during FU phase week 36 (negative at week 48); B-cell
depletion was as expected in all.
No new or unexpected safety ﬁndings occurred in either the
week 24 to 48 FU or IFU periods. AEs leading to withdrawal
were reported in ≤2% of patients in each phase. In total, 8
patients discontinued because of AEs, mostly IRRs (2
patients) and decreased immunoglobulin G (2 patients).
Further pharmacokinetic results are presented in ﬁgure e-6,
links.lww.com/WNL/A435.
Discussion
This phase 2b study of subcutaneously administered
ofatumumab used a wide range of doses to explore a minimally
eﬀective dose as a potential treatment for relapsing-remitting
MS (RRMS). In the primary (week 0–12) eﬃcacy analysis,
Table 1 Baseline patient demographic characteristics (safety population) and disease history (mITT population)
Parameter
Placeboa
(n = 67)
Ofatumumab
3 mg every
12 wk (n = 34)
Ofatumumab
30 mg every
12 wk (n = 32)
Ofatumumab
60 mg every
12 wk (n = 34)
Ofatumumab
60 mg every
4 wk (n = 64)
Total
(n = 231)
Demographics (safety population), n 67 34 32 34 64 231
Sex, female, n (%) 46 (69) 22 (65) 24 (75) 22 (65) 41 (64) 155 (67)
Race, white, n (%) 65 (97) 34 (100) 31 (97) 34 (100) 61 (95) 225 (97)
Age, mean (SD), y 37.7 (9.38) 38·1 (8.29) 37.2 (10.04) 37.3 (9.67) 36.2 (9.57) 37.2 (9.36)
Body mass index, mean (SD), kg/m2 26.4 (6.86) 24.6 (3.42) 24.9 (3.77) 25.8 (4.31) 26.0 (5.85) 25.7 (5.43)
Disease history (mITT population), n 67 33 32 33 63 228
Clinical disease duration, mean (SD), y 3.92 (5.293) 3.90 (6.193) 6.10 (6.032) 3.59 (4.407) 4.68 (5.641) 4.38 (5.530)
Relapses (last 12 mo), mean (SD), n 1.3 (0.58) 1.4 (0.61) 1.3 (0.67)b 1.3 (0.60) 1.3 (0.70) 1.3 (0.3)
Relapses (last 24 mo), mean (SD), n 1.8 (0.78) 1.7 (0.91) 1.9 (1.12)b 1.9 (0.86) 1.8 (0.85) 1.8 (0.88)
Time since last relapse, mean (SD), d 150.3
(102.25)
128.9 (78.38) 184.7 (126.71) 165.5 (111.71) 139.8 (117.65) 151.3
(109.25)
MRI scan with active lesions (last 12 mo),
n (%)
29 (43) 15 (45) 11 (34) 15 (45) 28 (44) 98 (43)
Abbreviation: mITT = modified intent-to-treat.
a Patients randomized to the placebo group received 3 mg ofatumumab at week 12.
b n = 31.
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ofatumumab treatment across dosing regimens signiﬁcantly re-
duced new GdE lesions by 65% vs placebo. Early MRI time
points are often excluded in a priori eﬃcacy analyses2,3,7 because
disease activity initiated before the onset of action of therapy
could potentially dilute actual treatment eﬀect. In keeping with
this, post hoc analysis excluding week 0 to 4 MRI data revealed
an even greater (≥90%) reduction of newGdE lesions vs placebo
for ofatumumab at all doses ≥30 mg every 12 weeks. Similar
patterns were seen with multiple secondary imaging outcome
measures andwith the number of patients relapsing (weeks 4–12
less than weeks 0–4). Week 4 was used as the baseline in post
hoc analyses regardless of whether a conditioning dose of 3 mg
ofatumumab was administered. While it is possible that the
conditioning dose may have confounded the data, this study
focused on the steady-state outcome, and we do not believe the
conditioning dose would have had a signiﬁcant eﬀect on eﬃcacy
in the context of the overall exposure to the higher doses at
steady state.
Currently approved anti-CD20 treatment generally results in
complete/near-complete depletion of circulating B cells, al-
though it is not clear that this is necessary to achieve a high
level of eﬃcacy.4 Here, ofatumumab treatment resulted in
rapid dose-dependent B-cell depletion, which correlated with
eﬃcacy outcomes. A cumulative dose of 60 mg ofatumumab
administered over 12 weeks provided maximal beneﬁt, with
no additional suppression of lesions at higher cumulative
doses. Distinct from other studies of B-cell depletion in
RRMS, ofatumumab dosage regimens that did not completely
deplete circulating B cells could achieve robust treatment
eﬀects. Indeed, while the ofatumumab 3-mg dose every 12
weeks reduced circulating B-cell levels to ≈25% of baseline
(clearly less than the 5% of baseline achieved with 30- and 60-
mg dose every 12 weeks), it was surprisingly eﬀective in sig-
niﬁcantly reducing new T1 GdE lesions, with a 71% reduction
in mean rate of cumulative new GdE lesions from weeks 4 to
12. On the basis of post hoc analyses, ≥90% suppression of
Figure 2 Efficacy and pharmacodynamics
(A) Primary efficacy outcomemeasure: mean (95% confidence interval) cumulative number of GdE T1 lesions over time (all evaluable scans dataset). (B) New
lesion evolution (post hoc): mean number of newGdE T1 lesions at different MRI time points. Fromweek 8 through 24, the appearance of new GdE T1 lesions
was very low at doses of ≥30 mg every 12 weeks. (C) Pharmacodynamic response showing dose-response depletion of CD19 B cells and repletion kinetics
(safety population). Themedian time to repletion based on Kaplan-Meier estimates was ≈11months for the ofatumumab 3 and 30mg every 12weeks groups
and ≈14 months for the ofatumumab 60 mg every 12 and 4 weeks groups. (A) Faster repletion time (of ≈6 months) was noted for the placebo group, who
received a single ofatumumab 3mg dose at week 12 (and in whom32% did not deplete). Of those patients whose B cells had repleted by the end of the study,
the time to repletion appeared to generally be longer in the 60-mg ofatumumabdose groups comparedwith the other ofatumumabdose groups. Therewere
no signs of B-cell repletion during the 4-week interdosing interval with the every 4 weeks regimen. Some B-cell repletion was seem. GdE = gadolinium-
enhancing; LLN = lower limit of normal; q4w = every 4 weeks; q12w = every 12 weeks.
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Table 2 Planned and post hoc analyses of MRI endpoints
Endpoint Statistic Population Placeboa
Ofatumumab 3 mg
every 12 wk
Ofatumumab 30 mg
every 12 wk
Ofatumumab 60 mg
every 12 wk
Ofatumumab 60 mg
every 4 wk
Cumulative No. of new GdE T1 lesions
at weeks 12 and 24
No. mITT 67 33 30 33 63
Weeks 0–12b Mean rated mITT 0.99 0.35 0.35 0.35 0.35
Rate ratio (95% CI) mITT — 0.35 (0.221–0.548)e 0.35 (0.221–0.548)e 0.35 (0.221–0.548)e 0.35 (0.221–0.548)e
Weeks 4–12b (post hoc analysis) Mean rated mITT 0.84 0.25 0.09 0.08 0.07
Rate ratio (95% CI) mITT — 0.29 (0.133–0.643)f 0.10 (0.056–0.187)e 0.09 (0.049–0.170)e 0.08 (0.044–0.162)e
Week 0–24c Mean rated mITT 0.67 0.25 0.25 0.23 0.15
Rate ratio (95% CI) mITT 0.38 (0.20–0.72)g 0.38 (0.20–0.72)g 0.35 (0.19–0.65)e 0.23 (0.13–0.39)e
Cumulative No. of new/enlarging
total T2 lesions at week 12
No. mITT 67 32 30 33 63
Weeks 0–12b Mean rated mITT 1.04 0.42 0.37 0.42 0.30
Rate ratio (95% CI) mITT 1.00 0.40 (0.21–0.77)g 0.36 (0.18–0.69)f 0.40 (0.21–0.76)g 0.28 (0.16–0.49)e
Weeks 4–12b (post hoc analysis) Mean rated mITT 0.83 0.36 0.11 0.09 0.08
Rate ratio (95% CI) mITT 1.00 0.43 (0.20–0.90)h 0.13 (0.05–0.35)e 0.10 (0.04–0.27)e 0.10 (0.04–0.21)e
Cumulative No. of total
(new/persisting) GdE T1 lesions
at week 12
No. mITT 67 32 30 33 62
Weeks 0–12c Mean rated mITT 1.43 0.45 0.80 0.73 0.46
Rate ratio (95% CI) mITT 0.31 (0.16–0.60)e 0.56 (0.29–1.06) 0.51 (0.27–0.95)h 0.32 (0.19–0.55)e
Weeks 4–12 (post hoc analyses)c Mean rated mITT 1.35 0.37 0.47 0.43 0.31
Rate ratio (95% CI) mITT 0.27 (0.13–0.57)e 0.35 (0.17–0.75)e 0.32 (0.15–0.67)f 0.23 (0.12–0.42)e
Cumulative No. of new/enlarging
total T2 lesions at week 24
No. mITT 67 33 30 33 63
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GdEMRI lesion activity appeared to be achievable in this study
when B cells were depleted to a level of ≈32 cells/μL (although
the meaning and utility of such a measure require further
study). B-cell repletion between dosing was seen with the less
frequent administration of ofatumumab (i.e., every 12 weeks)
but not with the more frequent dosing (i.e., every 4 weeks), and
the time to repletion was longer for the higher-dose groups.
Repletion in all ofatumumab doses occurred faster than pre-
viously reportedwith anti-CD20 therapy.4,11 A dose response in
the kinetics of depletion-repletion suggested that higher-dose/
higher-frequency regimens result in greater depth of B-cell
depletion in tissues. This insight from patients is consistent with
anti-CD20 animal studies in which higher doses led to greater
depth of B-cell depletion in diﬀerent lymphoid tissues.12,13 In-
deed, the kinetics of repletionmay bemore informative than the
degree of initial depletion, especially with regimens that result in
near-complete depletion, where the nadir of circulating B cells
becomes an insensitive measure of both the depth of initial
B-cell depletion and the onset of repletion.
Prior ofatumumab exposure (in oncology, MS, and other auto-
immune disorders)7,14–17 has largely been intravenous, with the
exception of a limited single subcutaneous dose study in RA.8
We report overall good tolerability and no new/unexpected
safety ﬁndings with subcutaneous ofatumumab. As expected,
IRRs were the most common AEs; most were associated with
the ﬁrst dose of ofatumumab and resolved within 1 day of onset.
We found no beneﬁt of adding a (3 mg) conditioning dose.
Subcutaneous injection may have greater practicality compared
with intravenous administration requiring repeat access to health
care providers or infusion facilities. For some patients, more
control over the exact timing and circumstance of administration
would also be an advantage. As a fully human (compared with
chimeric or humanized18) antibody, ofatumumab would be
expected to exhibit very low immunogenicity, and indeed, no
HAHAs were reported in the ofatumumab intravenous study in
MS.7 In the current study, very low-titer HAHAs were reported
in 4 patients. Further investigation into the incidence of HAHAs
with ofatumumab is warranted.
Overall, this study demonstrates that ofatumumab has a high
capacity to suppress new brain MRI lesions with subcutaneous
administration at considerably lower (and incompletely B-cell
depleting) doses compared with those previously studied in
patients with MS. The ≥90% suppression of new T1 GdE and
T2 lesions with ofatumumab is consistent with the eﬀects
demonstrated by other anti-CD20 mAbs at doses resulting in
maximal peripheral B-cell depletion.2–4 The prospect of an
eﬃcacious subcutaneous B-cell–targeting therapy raises the
possibility of self-administration and therefore improvement
over intravenous administration in terms of both convenience
of use and the use of health care resources. It remains to be seen
whether the less profound depletion and faster repletion of
B cells achieved with ofatumumab will also translate into
a more favorable safety proﬁle. Our ﬁndings thus support in-
vestigation of low-dose subcutaneous ofatumumab in longer-
term eﬃcacy studies in RRMS.Ta
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Table 3 Overview of AEs of treatment phase and 24-week follow-up phase
AE Placeboa
Ofatumumab
3 mg every
12 wk
Ofatumumab
30 mg every
12 wk
Ofatumumab
60 mg every
12 wk
Ofatumumab
60 mg every
4 wk
Total
ofatumumab
Weeks 0–12, n 67 34 32 34 64 164
Any AE, n (%) 43 (64) 24 (71) 23 (72) 22 (65) 52 (81) 121 (74)
AE leading to withdrawal
from treatment
0 2 (6) 1 (3) 0 1 (2) 4 (2)
Treatment-related AEs 15 (22) 17 (50) 17 (53) 17 (50) 44 (69) 95 (58)
SAEs 0 0 0 1 (3) 4 (6) 5 (3)
Maximum intensity
Mild 22 (33) 13 (38) 11 (34) 11 (32) 29 (45) 64 (39)
Moderate 21 (31) 10 (29) 11 (34) 10 (29) 19 (30) 50 (30)
Severe 0 1 (3) 1 (3) 1 (3) 4 (6) 7 (4)
Weeks 12–24, n 65 31 30 33 60 219
Any AE, n (%) 40 (62) 16 (52) 15 (50) 20 (61) 27 (45) 118 (54)
AE leading to withdrawal
from treatment
0 2 (6) 0 0 1 (2) 3 (1)
Treatment-related AEs 17 (26) 9 (29) 6 (20) 9 (27) 9 (15) 50 (23)
SAEs 0 1 (3) 0 0 0 1 (<1)
Maximum intensity
Mild 20 (31) 9 (29) 8 (27) 10 (30) 19 (32) 66 (30)
Moderate 18 (280) 7 (23) 7 (23) 10 (30) 8 (13) 50 (23)
Severe 2 (3) 0 0 0 0 2 (<1)
24-wk FU Phase, N 66 31 32 33 59 220
Any AE, n (%) 35 (53) 17 (55) 15 (47) 16 (48) 28 (47) 111 (50)
AE leading to withdrawal
from treatment
0 0 1 (3) 0 0 1 (<1)
Treatment-related AEs 6 (9) 3 (10) 4 (13) 3 (9) 4 (7) 20 (9)
Serious AEs 5 (8) 1 (3) 1 (3) 0 2 (3) 9 (4)
Maximum intensity
Mild 16 (24) 8 (26) 7 (22) 9 (27) 16 (27) 56 (25)
Moderate 18 (27) 9 (29) 7 (22) 6 (18) 12 (20) 52 (24)
Severe 1 (2) 0 1 (3) 1 (3) 0 3 (1)
IFU phase, n 16 18 16 20 42 112
Serious AEs 0 0 0 0 2 (5) 2 (2)
Abbreviations: AE = adverse event; FU = follow-up; IFU = individualized follow-up; SAE = serious adverse event.
a Patients randomized to the placebo group received 3 mg of ofatumumab at week 12.
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Study question
What is the minimally eﬀective dose of the anti-CD20 monoclonal anti-
body ofatumumab in patients with relapsing forms of multiple sclero-
sis (RMS)?
Summary answer
Although all subcutaneous doses of ofatumumab demonstrated ef-
ﬁcacy, most robust eﬀects were observed for cumulative doses ≥30
mg/12 weeks, including doses that did not fully deplete circulating
B cells.
Classification of evidence
Class I.
What is known and what this paper adds
Selectively targeting B-cells using anti-CD20 monoclonal anti-
bodies is highly eﬀective at limiting disease activity in patients with
RMS. This study indicates that treatment with ofatumumab
decreases the number of new lesions on gadolinium-enhanced
MRI within 12 weeks of treatment initiation and may not require
complete depletion of circulating B cells.
Participants and setting
This phase 2b, multicenter, randomized, double-blind, placebo-
controlled study treated 231 patients with active RMS (mean age:
37.2 ± 9.36 years; mean disease duration: 4.38 ± 5.53 years), all
of whom had Expanded Disability Status Scale (EDSS)
scores ≤5.5.
Design, size, and duration
During the ﬁrst 24 weeks (treatment phase), eligible patients were
randomized (2:1:1:1:2) to placebo or ofatumumab at doses of 3, 30,
or 60 mg every 12 weeks, or 60 mg every 4 weeks, respectively. At
week 12, all patients in the placebo group received a single 3 mg
ofatumumab dose. The treatment schedule of all groups originally
randomized to receive ofatumumab was maintained weeks 12–24.
Following completion of the treatment phase, patient safety and B-cell
repletion were monitored during a 24-week follow-up phase. Begin-
ning at week 48, individual patients whose CD19+ B-lymphocyte
counts remained below the lower limit of normal and who had not
started other treatment entered an individualized follow-up phase.
Primary outcomes
The primary endpoint was deﬁned as the cumulative number of new
gadolinium-enhancing (GdE) brain lesions by week 12, the end of the
placebo-controlled period.
Main results and the role of chance
The study reported a 65% reduction in the mean rate of cumulative new
GdE lesions for all ofatumumab groups vs placebo between weeks 0–12
(rate ratio: 0.35; 95% conﬁdence interval [CI]: 0.221, 0.548; p < 0.001).
Moreover, ≥90% suppression of new lesions was observed at all cu-
mulative doses ≥30 mg between weeks 4 and 12 (0.08 [0.044, 0.162] to
0.10 [0.056, 0.187]) in a post hoc analysis.
Harms
Adverse events (AEs) were largely mild-to-moderate in severity. Inci-
dences of serious AEs (SAEs) were 3%, <1%, 4%, and <1% in weeks
0–12, 12–24, 24–48, and the individualized follow-up phase, respectively.
Bias, confounding, and other reasons for caution
The use of a conditioning dose may have confounded the data.
Generalizability to other populations
The results may be generalizable to other treatment regimens, al-
though further study is required.
Study funding/potential competing interests
This study was funded by GlaxoSmithKline. Go to Neurology.org/N
for full disclosures.
Table Baseline patient demographic characteristics (safety
population) and disease history (mITT population)
Disease
history (mITT
population), n 67 33 32 33 63 228
Clinical
disease duration,
mean (SD), y
3.92
(5.293)
3.90
(6.193)
6.10
(6.032)
3.59
(4.407)
4.68
(5.641)
4.38
(5.530)
Relapses
(last 12 mo),
mean (SD), n
1.3
(0.58)
1.4
(0.61)
1.3
(0.67)a
1.3
(0.60)
1.3
(0.70)
1.3
(0.3)
Relapses
(last 24 mo),
mean (SD), n
1.8
(0.78)
1.7
(0.91)
1.9
(1.12)a
1.9
(0.86)
1.8
(0.85)
1.8
(0.88)
a n = 31.
A draft of the short-form article was written by D. Drobish, a writer with Editage, a division of Cactus Communications. The authors of the full-
length article and the journal editors edited and approved the ﬁnal version.
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Disputes & Debates: Editors’ Choice
Steven Galetta, MD, FAAN, Section Editor
Reader response: An interdisciplinary response to contemporary
concerns about brain death determination
Joseph L. Verheijde (Scottsdale), Mohamed Y. Rady (Phoenix), and Michael Potts (Fayetteville)
Neurology® 2018;91:533–534. doi:10.1212/WNL.0000000000006150
We disagree with redeﬁning death “based on loss of clinical function of the heart and lungs or the
brain,”1 because it deviates from the legal deﬁnition of irreversible cessation of cardiorespiratory
function or of all functions of the brain, including the brainstem. The latter was intended to
protect the general public from injury and harm due to incorrect death declaration. The con-
temporary clinical criteria have been challenged on scientiﬁc, philosophical, legal, and religious
grounds.2–4 Lewis et al. reduce this opposition to “moral or religious beliefs, hope that a patient
will recover, or a lack of acceptance that a determination of brain death is the legal equivalent of
Editors’ note: An interdisciplinary response to contemporary
concerns about brain death determination
“An interdisciplinary response to contemporary concerns about brain death determination”
generated several readers’ responses. Commenting on the paper, Verheijde et al. argue that
cardiopulmonary death is not the equivalent to brain death and add that public trust in brain
death requires that there be zero false-positive determinations of death. Dr. Sethi suggests
that lawsuits related to brain death may be linked more to breakdowns in communication
between the medical teams and patient families rather than validity of determination of
death by neurologic criteria. Machado et al. suggest that ancillary tests should have a de-
cisive role in helping to delineate the brain death concept since clinical evaluation might
have pitfalls. Finally, Dr. Shabtai feels that it is an error to frame the debate as one of
religious or moral beliefs vs science, and suggests continued discussion, including broad
public debate. Authors Lewis et al. defend their article citing several prominent American
medical societies who support that brain death is equivalent to cardiopulmonary death.
They add that when the American Academy of Neurology guidelines are appropriately
applied, there are zero false-positive determinations of death. They suggest including
a social worker, psychologist, palliative care specialist, chaplain, and religious ﬁgure in
conversations about brain death. They explain that ancillary testing is recommended to
assess for lack of intracranial blood ﬂow or cerebral activity if a clinical evaluation cannot be
completed, but the gold standard for determination of brain death is a full clinical evalu-
ation. Further, they add that ancillary testing is imperfect and there are risks when per-
forming testing and interpreting the results. Finally, they remind the reader that the 1981
President’s Commission determined that death should be deﬁned based on complete loss
of function of the brain or the heart and lungs, but deferred to the medical community to
establish the speciﬁc criteria for determination of death. They stress that it is the medical
community’s responsibility to ensure that it is clear what constitutes “accepted medical
standards” for determination of death and that these criteria are adhered to consistently and
accurately.
Chafic Karam, MD, and Steven Galetta, MD
Neurology® 2018;91:533. doi:10.1212/WNL.0000000000006149
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a determination of cardiopulmonary death.”1 Religious objection stems from incongruence with
the hylomorphic Thomistic concept of death (body-soul connection) underlying Abrahamic
faith traditions. The “lack of acceptance” originates from low-level supporting scientiﬁc evidence
and absence of a coherent philosophical rationale.4 Furthermore, American Academy of Neu-
rology practice guidelines are more consistent with the brainstem rather than the whole-brain
death deﬁnition.
Public trust depends on determining death using a criterion with zero false-positives. Although
some have advocated silencing opposing views and ending dissension on brain death,5 we
welcome a broad public debate on the basis of contemporary (neuro)science advances, philo-
sophical reasoning, and anthropologic and theologic considerations.
1. Lewis A, Bernat JL, Blosser S, et al. An interdisciplinary response to contemporary concerns about brain death determination. Neurology
2018;90:423–426.
2. Joﬀe AR. Brain death is not death: a critique of the concept, criterion, and tests of brain death. Rev Neurosci 2009;20:187–198.
3. Yanke G, Rady MY, Verheijde JL. When brain death belies belief. J Relig Health 2016;55:2199–2213.
4. Shewmon DA. False-positive diagnosis of brain death following the pediatric guidelines: case report and discussion. J Child Neurol
2017;32:1104–1117.
5. Dubois JM. The ethics of creating and responding to doubts about death criteria. J Med Philos 2010;35:365–380.
Reader response: An interdisciplinary response to contemporary
concerns about brain death determination
Nitin K. Sethi (New York)
Neurology® 2018;91:534. doi:10.1212/WNL.0000000000006151
I read with interest the response of the interdisciplinary committee to contemporary concerns
about brain death determination.1 A deeper analysis of the lawsuits related to brain death
determination reveals that, in a signiﬁcant number, the issue was not the validity of de-
termination of death by neurologic criteria or the inconsistency with the 2010 American
Academy of Neurology practice guideline prevalent among diﬀerent institutions in the United
States and abroad; rather, the crux of the problem lies in the manner death by neurologic criteria
was conveyed to the family by the physician.
While patients who meet either cardiopulmonary or brain death criteria are in both cases legally
dead, it is far easier and ﬁnal for the grieving family to accept that their loved one is dead when
the heart has stopped beating than to be told that the brain has been irreversibly damaged and
that the “death of the brain” is equivalent to the “death of the person as a whole.”
“They say you die twice. One time when you stop breathing and a second time, a bit later on,
when somebody says your name for the last time” is a quote attributed to Banksy. A large
segment of the public still feels that one dies twice. Once when the heart stops and once when
the brain stops. The ﬁrst step to dispelling this myth is to stop using terms such as “brain death”
or “death by neurologic criteria” when talking to a patient’s family. “Death is death no matter
whether the heart dies or the brain dies” is the message we need to get out.
1. Lewis A, Bernat JL, Blosser S, et al. An interdisciplinary response to contemporary concerns about brain death determination. Neurology
2018;90:423–426.
Copyright © 2018 American Academy of Neurology
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Reader response: An interdisciplinary response to contemporary
concerns about brain death determination
Calixto Machado, Mario Estevez (Havana), Phillip A. DeFina (Flanders), and Gerry Leisman (Haifa)
Neurology® 2018;91:535. doi:10.1212/WNL.0000000000006152
We read with interest the Contemporary Issues by Lewis et al.1 Previously, Dr. Bernat defended
the whole-brain concept of brain death (BD),2 and the US President’s Commission recom-
mended its adoption by all US states.3 In 2015, Wijdicks stated, “the irreversible absence of
functions of the brainstem is the necessary and suﬃcient component of brain death.”4 This view
fully pertains to brainstem death, and not to the whole-brain criterion.5 The American Academy
of Neurology summit concluded that “BD is deﬁned by irreversible loss of consciousness and
brainstem function,” according to the whole-brain criterion.1
Well-designed surveys have shown discrepancies with the American Academy of Neurology
guidelines on the use of ancillary tests.1,5 ECG monitoring is routinely used by physicians to
diagnose a cardiac arrest. Patients’ relatives more easily accept death when an ECG isoelectric
line is observed in bedside monitors. There is no perfect conﬁrmatory test, as clinical evaluation
might have pitfalls. Ancillary tests should have a decisive role in helping to delineate the BD
concept, as they have for outlining the cardiorespiratory view of death.
Is there a diagnosis of any disease in which a conﬁrmatory test is not used? BD determination is
the most challenging diagnosis. This might signiﬁcantly reduce institutional protocol diver-
gences in BD diagnosis.5
1. Lewis A, Bernat JL, Blosser S, et al. An interdisciplinary response to contemporary concerns about brain death determination. Neurology
2018;90:423–426.
2. Bernat JL. A defense of the whole-brain concept of death. Hastings Cent Rep 1998;28:14–23.
3. DigitalGeorgetown. Deﬁning death: medical, legal and ethical issues in the determination of death [online]. Available at: hdl.handle.net/
10822/559345. Accessed February 10, 2018.
4. Wijdicks EFC. The clinical determination of brain death: rational and reliable. Semin Neurol 2015;35:103–104.
5. Machado C, Estevez M, DeFina PA, et al. A reason for care in the clinical evaluation of function on the spectrum of consciousness. Funct
Neurol Rehab Ergon (in press 2017).
Reader response: An interdisciplinary response to contemporary
concerns about brain death determination
David Y. Shabtai (Boca Raton)
Neurology® 2018;91:535–536. doi:10.1212/01.wnl.0000544244.66565.8d
It is reassuring that questions surrounding the proper diagnosis of brain death are continuously
being debated.1 However, while Lewis et al. acknowledge the existence of dissent regarding
accepting brain death as the death of the individual, they frame the debate as one of beliefs vs
science. This is an error.
The question of deﬁning death is not one that lends itself to assertions by medical associations
or physicians. Science andmedicine are disciplines of facts and numbers, answering questions that
ask what or how, but not questions of why. Indeed, assessing whether the criteria for death have
been met requires precise medical determination. It necessitates expertise and precision, evalu-
ating advancing technologies, and diagnostic acumen to evaluate speciﬁc physiologic parameters.
However, establishing those very criteria are questions of values and ethics. Selecting particular
physiologic parameters for death requires assessing the values, ethics, and morals behind these
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decisions.2 These are not questions of science, but rather of philosophy and ethics. These are
not questions to which additional scientiﬁc data are relevant, but must reﬂect the values and
ethics of society.
Continued discussion—including broad public debate—should not only be welcome, but is
necessary. Steering this discourse toward medical associations assumes that they accurately and
eﬀectively represent the values of society—an assertion that many would not quickly accept.
1. Lewis A, Bernat JL, Blosser S, et al. An interdisciplinary response to contemporary concerns about brain death determination. Neurology
2018;90:423–426.
2. Veatch RM. Transplantation Ethics. Washington: Georgetown University Press; 2000.
Copyright © 2018 American Academy of Neurology
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Ariane Lewis (New York), James L. Bernat (Lebanon), Sandralee Blosser (Pittsburgh),
Richard J. Bonnie (Charlottesville), Leon G. Epstein (Chicago), John Hutchins (Minneapolis),
Matthew P. Kirschen (Philadelphia), Michael Rubin (Dallas), James A. Russell (Burlington),
Justin A. Sattin (Madison), Eelco F.M. Wijdicks (Rochester), and David M. Greer (Boston)
Neurology® 2018;91:536–538. doi:10.1212/WNL.0000000000006154
We appreciate the interest and comments of Verheijde et al., Dr. Sethi, Machado et al., and
Dr. Shabtai.
We acknowledge that, as evidenced by the comment of Verheijde et al., some people, including
physicians, do not believe that brain death is equivalent to cardiopulmonary death. Nonethe-
less, our multidisciplinary statement equating the two is supported by prominent American
medical societies including the American Academy of Neurology, American Academy of Pe-
diatrics, American College of Chest Physicians, American College of Radiology, American
Neurological Association, American Society of Neuroradiology, Child Neurology Society, and
Neurocritical Care Society.1 Of course, we welcome continued discussion on this topic, par-
ticularly if relevant scientiﬁc data emerge.
We heartily agree with Verheijde et al. that public trust in brain death requires that there be zero
false-positive determinations of death. Review of the literature from 1996 to 2009 demonstrated
that when the American Academy ofNeurology guidelines were appropriately applied, there were
zero false-positive determinations of death.2 However, inconsistent adherence to the guidelines
can lead to false-positive determinations. We are working to avoid this by (1) promoting edu-
cational initiatives and brain death credentialing programs to ensure physicians performing
evaluations for brain death determination are knowledgeable about the guidelines and comply
with them, and (2) advocating for regulatory oversight to ensure determinations are performed
according to the guidelines. Any alleged false-positive determination requires careful study.
To respond to Dr. Sethi’s thoughtful comments: we believe that the triggers for the recent
lawsuits related to brain death are multifactorial, but we agree that it is possible that breakdowns
in communication between the medical teams and patient families had a role. Educating
families about brain death can be challenging. It is important for physicians to bear in mind that
religious formulations of death vary and that the public’s perception of brain death is often
based on misinformation published in the media and misrepresentations depicted in television
and ﬁlm.3–5 It is imperative that physicians who are involved in brain death determination be
536 Neurology | Volume 91, Number 11 | September 11, 2018 Neurology.org/N
Author disclosures are available upon request (journal@neurology.org).
Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
adept at patiently explaining the concept of brain death and its implications while demon-
strating cultural competence, compassion, and empathy for families. Discussions about brain
death may precipitate a deluge of emotions including anger, fear, depression, distrust, and even
guilt. As a result, consideration should be given to including a social worker, psychologist,
palliative care specialist, chaplain, and/or religious ﬁgure in conversations about brain death.
Recommendations by Lewis et al.6 for pediatric intensivists on communicating with families
about brain death are universally applicable and should be included in brain death de-
termination training sessions.
In regard to the concern by Machado et al. of protocol divergence, the legal and medical
standards for determination of death by neurologic criteria in patients of all ages in the United
States require irreversible cessation of all functions of the whole brain, including the
brainstem.2,7,8 The guidelines for determination of brain death in both pediatric and adult
patients deﬁne death based on clinical criteria. Ancillary testing is recommended to assess for
lack of intracranial blood ﬂow or cerebral activity if a clinical evaluation cannot be completed,
but the gold standard for determination of brain death is a full clinical evaluation.2,8 However,
we agree with Machado et al. that the clinical evaluation can have pitfalls. The solution to this is
not mandating ancillary testing, though. Ancillary testing is imperfect and there are risks both
when performing testing and interpreting the results.9 Despite this, some institutions require
ancillary testing.10 To address these issues and ensure brain death determinations are consistent
and accurate, we aim to (1) advocate for uniform institutional policies throughout the United
States by implementing regulatory oversight, and (2) develop educational initiatives and cre-
dentialing programs.
We agree with Dr. Shabtai that the task of deﬁning death requires input from specialists in
a diverse range of ﬁelds. Accordingly, in 1981, the President’s Commission for the Study of
Ethical Problems in Medicine and Biomedical and Behavioral Research addressed this topic
with emphasis on the question of whether brain death should be incorporated into the societal
deﬁnition of death.11 This committee was composed of experts in bioethics, epidemiology,
health economics, law, medicine, nursing, philosophy, public health, research science, and
sociology and sought counsel from the American Bar Association, the American Medical
Association, the National Conference of Commissioners on Uniform State Laws, and religious
oﬃcials.11 The President’s Commission determined that death should be deﬁned based on
complete loss of function of the brain (including the brainstem) or the heart and lungs, but
deferred to the medical community to establish the speciﬁc criteria for determination of death.
All 50 states adopted the deﬁnition of death the President’s Commission created, or a variation
thereof.12 As a result, it is the medical community’s responsibility to ensure that it is clear what
constitutes “accepted medical standards” for determination of death and that these criteria are
adhered to consistently and accurately. In addition, we would argue Dr. Shabtai’s implication
that medical societies are epistemologically conﬁned to the scientiﬁc method given that
physicians, such as Aristotle and Maimonides, have always been key contributors to the phil-
osophical discourse of medical ethics.
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CORRECTION
Subcutaneous ofatumumab in patients with relapsing-remitting
multiple sclerosis
The MIRROR study
Neurology® 2018;91:538. doi:10.1212/WNL.0000000000005929
In the article “Subcutaneous ofatumumab in patients with relapsing-remitting multiple
sclerosis: The MIRROR study” by A. Bar-Or et al.,1 there is an error in the Disclosure section.
The original disclosure statement erroneously indicated Dr. Bar-Or was an employee and
stockholder in GlaxoSmithKline. However, it should have read “A. Bar-Or has received con-
sulting fees from GlaxoSmithKline.” All other disclosures are correct as originally published.
The authors regret the error.
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